(2-Cinnamoylphenoxy)acetic acid | 126861-85-6

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 直链 1,3-二芳基丙烷
• 英文名称: (2-Cinnamoylphenoxy)acetic acid
• 英文别名: 2-[2-[(E)-3-phenylprop-2-enoyl]phenoxy]acetic acid
• CAS: 126861-85-6
• 化学式: C₁₇H₁₄O₄
• 分子量: 282.296
• InChiKey: LJAXJWSGQODKEC-ZHACJKMWSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  21
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.06
• 拓扑面积：
  63.6
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  (2-Cinnamoylphenoxy)acetic acid 在 4-二甲氨基吡啶 、 草酰氯 、 N,N-二甲基甲酰胺 作用下， 以 苯 为溶剂， 反应 2.5h， 生成 (2-sulfanylidenepyridin-1-yl) 2-[2-[(E)-3-phenylprop-2-enoyl]phenoxy]acetate
  参考文献：
  名称：

  Ahmad-Junan, S. Asiah; Walkington, Andrew J.; Whiting, Donald A., Journal of the Chemical Society. Perkin transactions I, 1992, # 18, p. 2313 - 2320

  摘要：

  DOI：
• 作为产物：
  描述：

  (2E)-1-(2-羟基苯基)-3-苯基-2-丙烯-1-酮 生成 (2-Cinnamoylphenoxy)acetic acid
  参考文献：
  名称：

  Biomimetic radical cyclisations: Synthesis and biosynthesis of benzodihydro-pyrans and -furans

  摘要：

  DOI：

  10.1016/s0040-4039(01)80787-5

文献信息

• 1,3-bis-(substituted-phenyl)-2-propen-1-ones and their use to treat VCAM-1 mediated disorders
  申请人：Atherogenics Pharmaceuticals, Inc.

  公开号：US20030236298A1

  公开（公告）日：2003-12-25

  It has been discovered certain 1,3-bis-(substituted-phenyl)-2-propen-1-ones, including compounds of formula (I) inhibit the expression of VCAM-1, and thus can be used to treat a patient with a disorder mediated by VCAM-1. Examples of inflammatory disorders that are mediated by VCAM-1 include, but are not limited to arthritis, asthma, dermatitis, cystic fibrosis, post transplantation late and chronic solid organ rejection, multiple sclerosis, systemic lupus erythematosis, inflammatory bowel diseases, autoimmune diabetes, diabetic retinopathy, rhinitis, ischemia-reperfusion injury, post-angioplasty restenosis, chronic obstructive pulmonary disease (COPD), glomerulonephritis, Graves disease, gastrointestinal allergies, conjunctivitis, atherosclerosis, coronary artery disease, angina and small artery disease.

  已经发现了某些1,3-双-(取代苯基)-2-丙烯-1-酮，包括公式(I)化合物抑制VCAM-1的表达，因此可用于治疗受VCAM-1介导的疾病的患者。VCAM-1介导的炎症性疾病的例子包括但不限于关节炎、哮喘、皮炎、囊性纤维化、移植后晚期和慢性实体器官排斥、多发性硬化症、系统性红斑狼疮、炎症性肠病、自身免疫性糖尿病、糖尿病视网膜病变、鼻炎、缺血再灌注损伤、血管成形术后再狭窄、慢性阻塞性肺疾病（COPD）、肾小球肾炎、格雷夫斯病、胃肠道过敏、结膜炎、动脉粥样硬化、冠状动脉疾病、心绞痛和小动脉疾病。
• Chalcone derivatives and their use to treat diseases
  申请人：Ni Liming

  公开号：US20060189549A1

  公开（公告）日：2006-08-24

  The invention relates to compounds, pharmaceutical compositions and methods of using compounds of the general formula or its pharmaceutically acceptable salt or ester, wherein the substituents are defined in the application.

  本发明涉及一般式化合物、药物组合物及使用该一般式化合物或其药学上可接受的盐或酯的方法，其中取代基在申请中定义。
• Sulfonamide-substituted chalcone derivatives and their use to treat diseases
  申请人：Worsencroft J. Kimberly

  公开号：US20050049236A1

  公开（公告）日：2005-03-03

  The invention relates to compounds, pharmaceutical compositions and methods of using compounds of the general formula or its pharmaceutically acceptable salt or ester, wherein the substituents are defined in the application.

  该发明涉及一般式的化合物、药物组成物和使用该化合物的方法，或其药学上可接受的盐或酯，其中取代基在申请中有定义。
• Process of making chalcone derivatives
  申请人：——

  公开号：US20040181075A1

  公开（公告）日：2004-09-16

  This invention is a novel methods of manufacturing chalcones that includes reacting a carbon-linked heteroaryl or heterocyclic substituted benzaldehyde with an acetophenone in a solvent or mixture of solvents in the presence of LiOMe. Also provided are new chalcones for the treatment of medical conditions.

  这项发明涉及一种新的合成查尔酮的方法，包括在溶剂或混合溶剂中，在LiOMe的存在下，将含有碳链的杂芳基或杂环取代苯甲醛与苯乙酮反应。同时提供了用于治疗医疗状况的新型查尔酮。
• 1,3-Bis-(substituted-phenyl)-2-propen-1-ones and their use to treat VCAM-1 mediated disorders
  申请人：Meng Q. Charles

  公开号：US20060258735A1

  公开（公告）日：2006-11-16

  It has been discovered certain 1,3-bis-(substituted-phenyl)-2-propen-1-ones, including compounds of formula (I) inhibit the expression of VCAM-1, and thus can be used to treat a patient with a disorder mediated by VCAM-1. Examples of inflammatory disorders that are mediated by VCAM-1 include, but are not limited to arthritis, asthma, dermatitis, cystic fibrosis, post transplantation late and chronic solid organ rejection, multiple sclerosis, systemic lupus erythematosis, inflammatory bowel diseases, autoimmune diabetes, diabetic retinopathy, rhinitis, ischemia-reperfusion injury, post-angioplasty restenosis, chronic obstructive pulmonary disease (COPD), glomerulonephritis, Graves disease, gastrointestinal allergies, conjunctivitis, atherosclerosis, coronary artery disease, angina and small artery disease.

  已经发现某些1,3-双-(取代苯基)-2-丙烯-1-酮，包括公式（I）化合物抑制VCAM-1的表达，因此可以用于治疗由VCAM-1介导的患者疾病。由VCAM-1介导的炎症性疾病的例子包括但不限于关节炎，哮喘，皮炎，囊性纤维化，移植后晚期和慢性实体器官排斥，多发性硬化症，系统性红斑狼疮，炎症性肠病，自身免疫性糖尿病，糖尿病视网膜病变，鼻炎，缺血再灌注损伤，血管成形术后再狭窄，慢性阻塞性肺疾病（COPD），肾小球肾炎，Graves病，胃肠道过敏，结膜炎，动脉粥样硬化，冠状动脉疾病，心绞痛和小动脉疾病。